2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Congenital Heart Disease (CHD) Market?

The rise of maternal diabetes occurrences is anticipated to fuel the congenital heart disease (CHD) market’s expansion. Maternal diabetes, also known as gestational diabetes mellitus (GDM), is a type of diabetes that develops in women who were not previously diagnosed with the condition prior to their pregnancy. This form of diabetes is triggered by lifestyle modifications, such as a lack of physical activity and unhealthy food choices, as well as a general upsurge in obesity among women within the childbearing age range. An increase in maternal diabetes can result in congenital heart disease (CHD) in newborns, with high blood glucose levels interfering with fetal heart development. Excess glucose in the mother’s bloodstream can hinder the standard development process of the child’s heart, raising the chances of CHD. For instance, the National Health Service, a government department in the UK, reported in October 2023 that there was a rise from 4.9% in 2021 to 6.6% in 2022 in adverse pregnancy outcomes for women diagnosed with type 2 diabetes. As a result, the surge in maternal diabetes occurrences is contributing to the growth of the congenital heart disease (CHD) market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

What is the Predicted Annual Growth Rate of theCongenital Heart Disease (CHD) Market Impact Industry Trends by 2034?

The market size for congenital heart disease (CHD) has seen considerable growth in the last few years. It’s predicted to increase from $4.42 billion in 2024 to $4.87 billion in 2025 with a compound annual growth rate (CAGR) of 10.1%. The previous upward trend can be linked to the rising occurrence of risk elements like obesity and smoking, advancements in diagnostic technologies, an enlarging elderly population, more effective awareness campaigns, improved reimbursement strategies, and a heightened financial commitment to research and development.

The market for congenital heart disease (CHD) is projected to experience significant expansion in the coming years, escalating to a value of $7.05 billion by 2029 with a compound annual growth rate (CAGR) of 9.7%. Factors contributing to this growth within the forecast period include broader access to healthcare in developing areas, ongoing advancements in cardiac imaging technologies, increased awareness initiatives focusing on early diagnosis and management, escalating worldwide healthcare spending, and the evolution of personalized medicine. Key trends influencing this period reveal a shift towards minimally invasive surgical methods, growing application of telemedicine for remote patient consultation and observation, a surge in the pursuit of personalized treatment strategies, the creation of innovative implantable devices having improved performance and lifespan, along with the introduction of artificial intelligence and machine learning into diagnostic and medicinal procedures.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15545

What Are the Key Market Innovations in theCongenital Heart Disease (CHD) Market Over the Coming Years?

Key players in the congenital heart disease market are innovating non-surgical heart valves to enhance patient health and lifestyle. Transcatheter heart valves, an alternative to traditional open-heart surgery, are medical instruments used to cure heart valve diseases. For example, Medtronic, an American medical technology firm, re-launched its Harmony Transcatheter Pulmonary Valve (TPV) System in February 2023. It offers a revolutionary, minimally invasive substitute to open-heart surgery for individuals with congenital heart disease, specifically those dealing with native or surgically corrected right ventricular outflow tract (RVOT) abnormalities. This is the first FDA-approved valve exclusively for the right side, giving a non-surgical route for patients experiencing severe pulmonary valve regurgitation. The Harmony TPV System got the green light from the U.S. FDA back in 2021 and was reissued after a voluntary recall. This reflects Medtronic’s promise to driving innovation for patients affected by congenital heart disease.

Who Are the Top Companies Driving Innovation and Growth in theCongenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (CHD) market are Pfizer Inc., AstraZeneca Plc, Abbott Laboratories, Novartis AG, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Neusoft Corp., Carestream Health, Midmark Corporation, Contec Medical Systems, Randox Laboratories Ltd., Schiller AG, BPL Medical Technologies, Compumedics Limited, Biocare Medical, Bionet America Inc., Nasan Medical Electronics Pvt Ltd

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Key Market Segments Comprise the Congenital Heart Disease (CHD) Market and Drive Its Revenue Growth?

The congenital heart disease (CHD) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray,  Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Which Regions Are Emerging as Leaders in the Congenital Heart Disease (CHD) Market?

North America was the largest region in the congenital heart disease (CHD) market in 2023. The regions covered in the congenital heart disease (CHD) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2025, By The Business Research Company:

Cardiovascular Digital Solutions Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-digital-solutions-global-market-report

Cardiovascular Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-devices-global-market-report

Cardiovascular Ultrasound Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: